Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 9Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 119Thoracic 46Gynecologic 42Breast 32CNS 15Genitourinary 10Tumor-Agnostic 5Sarcoma 2Other solid neoplasm 1NET 1Lymphoid 1Head & Neck 1Endocrine 1Classical hematology 1

Conditions

Lymphoma, B-Cell 1

Interventions

Rituximab 238Cyclophosphamide 192Vincristine 164Doxorubicin 150Prednisone 126Methotrexate 80Cytarabine 79Etoposide 78Dexamethasone 72Radiotherapy 60Bendamustine Hydrochloride 58Mercaptopurine 46Lenalidomide 42pegaspargase 41Prednisolone 38Filgrastim 38ibrutinib 37fludarabine 36Bleomycin 36Daunorubicin 35obinutuzumab 34Asparaginase 33Leucovorin 29venetoclax 28Granulocyte Colony-Stimulating Factor 28Chlorambucil 27Calcium Dobesilate 27Gemcitabine 26Vinblastine 25Thioguanine 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Bevacizumab × Lymphoid × Clear all
NCT00486759 2017-07-25

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Hoffmann-La Roche

Phase 3 Terminated
787 enrolled 8 charts
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡